The latest from CDMOs, CMOs, and suppliers featuring Euroapi, MilliporeSigma, Schott Pharma, CoreRx and AustinPx.  

Chemicals/Chemical API Manufacturing 
* Euroapi Reorganizes Executive Leadership 
Biologics Manufacturing 
* MilliporeSigma Investing $326 M in Biologic Mfg Facility Expansion
Formulation Development/Drug Product Manufacturing 
* CoreRx Completes $130-M Acquisition of Societal CDMO 
* AustinPx Expands Early-Phase Mfg Capabilities 
Packaging 
* Schott Pharma Investing $371 M to Build Prefilled Syringe Mfg Facility

---

Chemicals/Chemical API Manufacturing 

Euroapi Reorganizes Executive Leadership 
Euroapi, a CDMO of small-molecule active pharmaceutical ingredients and intermediates that was previously spun off from Sanofi in 2022, has announced changes to its executive leadership. The announcement follows the naming of a new CEO and restructuring plan that the company announced in February (February 2024). 

In its most recent moves,  Guillaume Rosso, formerly Chief Strategy and M&A Officer, Euroapi, has been appointed as Chief Commercial Officer, succeeding Laurent Alexandre, currently in that role, who has decided to pursue other opportunities outside of the company. The new Executive Committee will now be composed of: (1) Antoine Delcour, Chief Financial Officer; (2) Thierry Durand, Chief R&D Officer; (3) Ute Herzog, Chief Human Resources Officer; (4) Cécile Maupas, Chief CDMO Officer; (5) Guillaume Rosso, Chief Commercial Officer; and (6) David Seignolle, Chief Operating Officer. 

Source: Euroapi 

---

Biologics Manufacturing 

MilliporeSigma Investing $326 M in Biologic Mfg Facility Expansion 
MilliporeSigma, the life science business of Merck KGaA, has announced an investment of more than EUR 300 million ($326 million) into a new bioprocessing production center in Daejeon, South Korea.  

MilliporeSigma’s new Bioprocessing Production Center will provide products such as dry-powder cell culture media, process liquids, pre-GMP small-scale manufacturing, and sterile sampling systems. Covering an area of 43,000 square meters, the facility will include production capacities, a distribution center, and an automated warehouse. The investment is expected to create approximately 300 additional jobs by the end of 2028. 

Source: MilliporeSigma 

---

Formulation Development/Drug Product Manufacturing 

CoreRx Completes $130-M Acquisition of Societal CDMO 
CoreRx, a Clearwater, Florida-based CDMO of drug products, has completed its acquisition of Societal CDMO, a Gainesville, Georgia-based CDMO of drug products, for $130 million. The acquisition was announced in February 2024. 

Under the agreement, CoreRx’s tender offer to acquire all of the issued and outstanding shares of common stock of Societal CDMO, at a purchase price of $1.10 per share expired on April 5, 2024. A total of 102,588,622 shares were validly tendered and not properly withdrawn, representing approximately 92.8% of the issued and outstanding shares. Following completion of the tender offer, CoreRx completed the acquisition of Societal CDMO through a previously planned second-step merger. As a result of the merger, Societal CDMO became a wholly owned subsidiary of CoreRx.  

Source: CoreRx 

---

AustinPx Expands Early-Phase Mfg Capabilities 
AustinPx, a Georgetown, Texas-based CDMO of drug products, has announced investments to enhance its early-phase development and manufacturing capabilities.  

The investments include acquisitions of a 3P Innovations API-in-capsule filling machine, a FT4 Powder Rheometer, and the STYL’One Nano compaction simulator. The expanded capabilities are now available for use.  

Source: AustinPx 

---

Packaging 

Schott Pharma Investing $371 M to Build Prefilled Syringe Mfg Facility 
Schott Pharma, a Mainz, Germany-based supplier of drug-packaging systems, has announced an investment of $371 million to build a facility to manufacture prefillable polymer syringes for deep-cold storage and transportation of mRNA medications. 

The new site, located in Wilson, North Carolina, will have the capability to produce glass prefillable syringes for glucagon-like peptide-1 (GLP-1) therapies to treat diseases such as diabetes or obesity. The project will add 401 jobs to the region, with groundbreaking expected by the end of 2024, and projected operations starting in 2027. 

Source: Schott Pharma